查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1284255

到 2028 年的基因分型市場預測——按產品和服務、技術、應用、最終用戶和地區進行的全球分析

Genotyping Market Forecasts to 2028 - Global Analysis By Product & Service, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

據Stratistics MRC預測，2022年全球基因分型市場規模將達到278.9億美元，2028年將達到1014.1億美元，複合年增長率為24.0%，預計

基因分型是一種利用個體的 DNA 序列通過生物學實驗檢查其基因構成變化的方法。 這種方法有助於科學家檢查遺傳異常，例如 DNA 的結構變異和單核甘酸多態性。 減少錯誤並提供有效結果的創新技術的出現，以及癌症、糖尿病和阿爾茨海默病等目標疾病患病率的上升，正在推動市場的增長。

根據世界衛生組織的數據，2020 年全球有 1910 萬新癌症患者使用基因分型進行診斷。 人類乳頭瘤病毒 (HPV) 和乙型肝炎病毒 (HBV)/丙型肝炎病毒 (HCV) 等致癌病毒約佔全球癌症死亡人數的 20%。

市場動態：

驅動程序

DNA 測序的技術進步和成本下降

小型化、自動化、較低的總成本、操作靈活性和包含多參數檢測都是由技術突破實現的。 這些極大地提高了 DNA 測序的多功能性和使用，使醫生能夠專注於關鍵選擇，例如通過不同的基因分型研究選擇治療目標並確定治療目標的優先級。 因此，毛細管電泳、微陣列、PCR 和測序等技術在臨床研究和藥物開發等領域的應用越來越廣泛。

約束

設備成本高

進行基因分型檢測所需的設備非常昂貴，引進需要大量資金。 基因分型儀器因其先進的特性和功能而價格昂貴。 製藥公司和研究實驗室需要大量此類系統，需要大量投資購買大量昂貴的基因分型設備。 此類儀器總擁有成本的增加是由維護成本和其他間接成本（包括樣品和人工成本）驅動的。 因此，學術研究機構難以安裝或擴建 NGS 技術等尖端研究設施，阻礙了市場增長。

機會

拓展應用領域

基因分型系統的應用包括藥物基因組學、診斷研究、個性化醫療和法醫學。 此外，該技術還適用於各種獸醫要求、食品安全和質量檢查以及農村和工業環境中的環境條件。 目前，由於需要更好的治療選擇和高發病率，人類診斷學和藥物基因組學是具有巨大標記潛力的領域。 這些領域還需要大規模和快速的基因分型分析，為市場增長創造廣闊的機會。

威脅

基因分型數據管理調查

基因分型調查提供了大量的定量和定性數據。 過去，這些數據是手動存儲的，但這是一個重大挑戰，因為可以在短短幾個小時內創建 TB 的數據。 隨著用於存儲基因分型數據的數據庫的發展，技術進步使得自動化數據存儲成為可能。

COVID-19 的影響：

技術進步、癌症和基因異常發生率的增加，以及對精準醫學研究的研究投資增加，都是導致擴張的因素。 大流行增加了對 COVID-19 基因分型試劑盒的需求，這對基因分型業務產生了積極影響。 使用 SNP 基因分型發現了 COVID-19 的基因突變。 隨著政府機構以及製藥和生物技術公司加速研究，預計基因分型行業將受到政府資金增加的推動，尤其是基因組研究。

預計在預測期內最大的產品和服務部門

在產品和服務領域，各種試劑的可用性，由於全球基因分型檢測量的增加對試劑的需求增加，以及醫院和診斷對基因分型試劑和試劑盒的需求實驗室正在增加。據推測，高增長是由於部署所需的資本支出相對較低等因素造成的。

藥物基因組學有望在預測期內見證最高的複合年增長率

在預測期內，藥物基因組學領域預計將以最高複合年增長率增長。 藥物基因組學研究基因如何影響個體的藥物反應。 該領域將基因及其作用的研究與醫學科學相結合，以創造根據個人基因特徵提供的有效且安全的治療方法。 未來，它有望用於創造個性化藥物，以解決心血管疾病、阿爾茨海默病、癌症和哮喘等各種健康問題，從而推動市場增長。

市場份額最高的地區：

由於技術先進產品的使用增加、大型製藥和生物製藥公司的存在、積極的政府政策以及醫療保健基礎設施的改善，北美將在預測期內佔據最高的市場份額。預計將佔據 此外，大公司的存在是促成該行業高市場份額的重要因素。 製藥公司對基因分型產品的需求不斷增長，政府投資不斷增加，技術先進的基因分型產品的採用率越來越高，醫療保健支出高

複合年增長率最高的地區：

由於該地區尚未開發的巨大潛力和越來越多的臨床試驗，預計亞太地區在預測期內的複合年增長率最高。 由於 FDA 建議將藥物基因組學研究和基因分型納入藥物發現過程以及藥物開發過程中對藥物基因組學的需求不斷增長等因素，預計市場將得到發展。 其他因素也可能有助於這種擴張，例如該地區製藥和生物製藥行業的技術發展和擴張。

主要發展：

2023 年 4 月，安捷倫和 Theragen Bio 合作推進韓國癌症基因組分析的生物信息學解決方案，新合作包括安捷倫的 SureSelect 癌症 CGP 檢測和 Theragen Bio 的區域分析結合軟件，轉變轉化研究並旨在加強精準腫瘤學

2023 年 4 月，安捷倫和 PathAI 合作為生物製藥研究和臨床應用提供人工智能分析開發解決方案，通過將 AI 納入 CDx 開發，安捷倫和 PathAI 將結合分析和機器學習分析構建算法集成解決方案。

2023 年 11 月，丹納赫啟動了 Beacon Initiative，這是第一個專注於基因治療創新的合作夥伴關係。投資於產品創新以推進重點突出的外部研發戰略。

這份報告提供了什麼

  • 區域和國家級細分市場的市場份額評估
  • 向新進入者提出戰略建議
  • 2020、2021、2022、2025 和 2028 年的綜合市場數據
  • 市場趨勢（驅動因素、制約因素、機會、威脅、挑戰、投資機會、建議）
  • 根據市場預測在關鍵業務領域提出戰略建議
  • 競爭格局映射關鍵共同趨勢。
  • 公司簡介，包括詳細的戰略、財務狀況和近期發展
  • 映射最新技術進步的供應鏈趨勢

免費定制優惠：

購買此報告的客戶將獲得以下免費定制選項之一：

  • 公司簡介
    • 其他市場參與者的綜合概況（最多 3 家公司）
    • 主要參與者的 SWOT 分析（最多 3 家公司）
  • 區域細分
    • 根據客戶的要求對主要國家/地區的市場估計/預測/複合年增長率（注意：基於可行性檢查）。
  • 競爭基準
    • 根據產品組合、區域影響力和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 概覽
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究來源
    • 二級研究來源
    • 假設

第三章市場趨勢分析

  • 司機
  • 約束因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第 5 章全球基因分型市場：按產品和服務分類

  • 基因分型服務
  • 生物信息學
    • 軟件
    • 服務
  • 設備
    • 分析儀
    • 音序器和放大器
  • 試劑和試劑盒

第 6 章全球基因分型市場：按技術分類

  • 順序
    • 焦磷酸測序
    • 下一代測序
    • 桑格測序
  • 微陣列
  • 聚合□鏈反應
    • 實時熒光定量PCR
    • 數字PCR
  • MALDI-TOF
  • 毛細管電泳
    • 限制性片段長度多態性
    • 單鏈構象多態性
    • 擴增片段長度多態性
  • 其他技術

第 7 章全球基因分型市場：按應用

  • 診斷和個性化醫療
  • 動物遺傳學
  • 藥物基因組學
  • 其他用途

第 8 章全球基因分型市場：最終用戶

  • 製藥和生物製藥公司
  • 學術機構
  • 研究和診斷實驗室
  • 其他最終用戶

第 9 章。全球基因分型市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東和非洲地區

第10章主要發展

  • 合同、夥伴關係、協作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Illumina Inc.
  • QIAGEN
  • Fluidigm Corporation
  • Agilent Technologies
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Eurofins Scientific Inc.
  • Bio-Rad Laboratories Inc.
  • GE Healthcare Inc.
  • Thermo Fisher Scientific
  • PerkinElmer
  • Pacific Biosciences of California
  • Integrated DNA Technologies
  • GENEWIZ
  • Biofortuna Limited
  • Precision Biomarker Resources, Inc.
  • TrimGen Corporation
Product Code: SMRC23087

According to Stratistics MRC, the Global Genotyping Market is accounted for $27.89 billion in 2022 and is expected to reach $101.41 billion by 2028 growing at a CAGR of 24.0% during the forecast period. Genotyping is a method that uses an individual's DNA sequence to examine genetic make-up variations using biological experiments. This method aids scientists in examining genetic anomalies such significant DNA structural variations and single nucleotide polymorphisms. The advent of innovative technologies that significantly reduce mistakes and produce effective findings, as well as the rising prevalence of target diseases including cancer, diabetes, and Alzheimer's, fuel the market's growth.

According to WHO, 19.1 million new cancer cases were diagnosed using genotyping globally in 2020. Cancer-causing viruses such as Human Papilloma Virus (HPV) and Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) are also responsible for about 20% of cancer deaths worldwide.

Market Dynamics:

Driver:

Technological advances and falling DNA sequencing costs

Miniaturisation, automation, lower overall costs, operational flexibility, and the inclusion of multi-parameter testing have all been made possible by technological breakthroughs. All of them have significantly improved the versatility and uses of DNA sequencing, freeing doctors to concentrate on important choices like selecting and prioritising therapeutic targets through diverse genotyping research. As a result, technologies like capillary electrophoresis, microarrays, PCR, sequencing, and sequencing have seen an increase in use in areas like clinical research and drug development.

Restraint:

High cost of equipment

The equipment needed to conduct genotyping testing is quite expensive, and a significant financial expenditure is needed to install it. Genotyping equipment is expensive since it has sophisticated features and capabilities. Such systems are needed by pharmaceutical corporations and research facilities in large quantities, necessitating considerable investments to buy numerous, expensive genotyping devices. The overall rise in the total cost of ownership of these instruments is brought on by maintenance costs as well as a number of other indirect costs, including sample and labour costs. As a result, academic and research institutions struggle to install and expand cutting-edge research facilities like NGS technology which are hindering the growth of the market.

Opportunity:

Expanding application fields

Applications for genotyping systems include pharmacogenomics, diagnostic research, individualised medicine, and forensics. Additionally, this technology is suitable for various veterinary requirements, testing for food safety and quality, and environmental conditions in rural and industrial settings. Currently, the demand for better treatment choices and the high frequency of disease make human diagnostics and pharmacogenomics segments that have great marker potential. These segments also require quick genotyping analysis on a wide scale creating a wide range of opportunities for the growth of the market.

Threat:

Research using genotyping data management

Genotyping investigations both quantitatively and qualitatively provide enormous amounts of data. Previously, this data was manually saved, but this posed a significant issue because up to terabytes of data may be created in only a few hours. Through the development of databases to store genotyping data, technological improvements have made it possible to automate the data storage procedure.

COVID-19 Impact:

Technology advances, an increase in the frequency of cancer and genetic abnormalities, and increased R&D investment for precision medicine research are all factors contributing to the expansion. The pandemic raised demand for COVID-19 genotyping kits, which has had a favourable effect on the genotyping business. The genetic variations of COVID-19 have been found using SNP genotyping. The genotyping industry is anticipated to be driven by an increase in government financing, particularly for genomic research, by governmental organisations and pharmaceutical and biotechnology firms to speed up research.

The product & service segment is expected to be the largest during the forecast period

The product & service segment is estimated to have a lucrative growth, due to the availability of a wide variety of reagents, the rising demand for reagents as a result of the increased volume of genotyping tests performed globally, and the relatively low capital expenditure needed to adopt reagents and kits for genotyping in hospitals and diagnostic labs are the factors contributing to the high growth.

The pharmacogenomics segment is expected to have the highest CAGR during the forecast period

The pharmacogenomics segment is anticipated to witness the highest CAGR growth during the forecast period. Pharmacogenomics is the study of how genes impact how an individual reacts to medications. This area integrates the study of genes and their roles with the science of pharmaceuticals to create effective, secure treatments that may be provided depending on a person's genetic profile. Pharmacogenomics will be utilised in the future to create custom medications to address a variety of health issues, such as cardiovascular disease, Alzheimer's disease, cancer, and asthma thus propelling the growth of the market.

Region with highest share:

North America is projected to hold the highest market share during the forecast period owing to the growing use of technologically sophisticated goods, the existence of significant pharmaceutical and biopharmaceutical businesses, pro-active government policies, and improvements in healthcare infrastructure. Another important element contributing to the high market share in this area is the existence of big companies. Growing demand from pharmaceutical companies for genotyping products, rising government investment, increasing adoption of technologically advanced genotyping products, high healthcare expenditures

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, due to the vast untapped potential and rising number of clinical trials being carried out in this area. Growth in the market is anticipated as a result of factors such as the FDA's recommendations to incorporate pharmacogenomics research & genotyping in the drug discovery process and the expanding demand for pharmacogenomics in the drug development process. Other causes, such as technical developments and the expanding pharma and biopharma industries in the area, might also be blamed for this expansion.

Key players in the market:

Some of the key players profiled in the Genotyping Market include Illumina Inc., QIAGEN, Fluidigm Corporation, Agilent Technologies, Danaher Corporation, Thermo Fisher Scientific Inc., Eurofins Scientific Inc., Bio-Rad Laboratories Inc., GE Healthcare Inc., Thermo Fisher Scientific, PerkinElmer, Pacific Biosciences of California, Integrated DNA Technologies, GENEWIZ, Biofortuna Limited, Precision Biomarker Resources, Inc. and TrimGen Corporation

Key Developments:

In April 2023, Agilent and Theragen Bio Partner to Advance Bioinformatic Solutions for Cancer Genomic Profiling in South Korea, New collaboration combines Agilent's SureSelect Cancer CGP assay and Theragen Bio's localized analysis software to transform translational research and enhance precision oncology

In April 2023, Agilent and PathAI Partner to Deliver AI-Powered Assay Development Solutions for Biopharma Research and Clinical Applications, By incorporating AI into CDx development, the partnership enables Agilent and PathAI to build integrated solutions with assays and machine learning analysis algorithms.

In Nov 2023, Danaher launches beacon initiative and its first partnership focused on gene therapy innovation, the program invests in product innovation to advance external R&D strategies with a focus on genomic medicines, precision diagnostics, next generation biomanufacturing, human systems, and data sciences.

Product & Services Covered:

  • Genotyping Services
  • Bioinformatics
  • Instruments
  • Reagents & Kit

Technologies Covered:

  • Sequencing
  • Microarrays
  • PCR
  • MALDI-TOF
  • Capillary Electrophoresis
  • Other Technologies

Applications Covered:

  • Diagnostic & Personalized Medicine
  • Animal Genetics
  • Pharmacogenomics
  • Other Applications

End Users Covered:

  • Pharmaceutical & Biopharmaceutical Companies
  • Academic Institutes
  • Research & Diagnostic Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Genotyping Market, By Product & Service

  • 5.1 Introduction
  • 5.2 Genotyping Services
  • 5.3 Bioinformatics
    • 5.3.1 Software
    • 5.3.2 Services
  • 5.4 Instruments
    • 5.4.1 Analyzers
    • 5.4.2 Sequencers & Amplifiers
  • 5.5 Reagents & Kit

6 Global Genotyping Market, By Technology

  • 6.1 Introduction
  • 6.2 Sequencing
    • 6.2.1 Pyrosequencing
    • 6.2.2 NGS
    • 6.2.3 Sanger Sequencing
  • 6.3 Microarrays
  • 6.4 PCR
    • 6.4.1 Real-Time PCR
    • 6.4.2 Digital PCR
  • 6.5 MALDI-TOF
  • 6.6 Capillary Electrophoresis
    • 6.6.1 Restricted Fragment Length Polymorphism
    • 6.6.2 Single-stranded Conformation Polymorphism
    • 6.6.3 Amplified Fragment Length Polymorphism
  • 6.7 Other Technologies

7 Global Genotyping Market, By Application

  • 7.1 Introduction
  • 7.2 Diagnostic & Personalized Medicine
  • 7.3 Animal Genetics
  • 7.4 Pharmacogenomics
  • 7.5 Other Applications

8 Global Genotyping Market, By End User

  • 8.1 Introduction
  • 8.2 Pharmaceutical & Biopharmaceutical Companies
  • 8.3 Academic Institutes
  • 8.4 Research & Diagnostic Laboratories
  • 8.5 Other End Users

9 Global Genotyping Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Illumina Inc.
  • 11.2 QIAGEN
  • 11.3 Fluidigm Corporation
  • 11.4 Agilent Technologies
  • 11.5 Danaher Corporation
  • 11.6 Thermo Fisher Scientific Inc.
  • 11.7 Eurofins Scientific Inc.
  • 11.8 Bio-Rad Laboratories Inc.
  • 11.9 GE Healthcare Inc.
  • 11.10 Thermo Fisher Scientific
  • 11.11 PerkinElmer
  • 11.12 Pacific Biosciences of California
  • 11.13 Integrated DNA Technologies
  • 11.14 GENEWIZ
  • 11.15 Biofortuna Limited
  • 11.16 Precision Biomarker Resources, Inc.
  • 11.17 TrimGen Corporation

List of Tables

  • Table 1 Global Genotyping Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Genotyping Market Outlook, By Product & Service (2020-2028) ($MN)
  • Table 3 Global Genotyping Market Outlook, By Genotyping Services (2020-2028) ($MN)
  • Table 4 Global Genotyping Market Outlook, By Bioinformatics (2020-2028) ($MN)
  • Table 5 Global Genotyping Market Outlook, By Software (2020-2028) ($MN)
  • Table 6 Global Genotyping Market Outlook, By Services (2020-2028) ($MN)
  • Table 7 Global Genotyping Market Outlook, By Instruments (2020-2028) ($MN)
  • Table 8 Global Genotyping Market Outlook, By Analyzers (2020-2028) ($MN)
  • Table 9 Global Genotyping Market Outlook, By Sequencers & Amplifiers (2020-2028) ($MN)
  • Table 10 Global Genotyping Market Outlook, By Reagents & Kit (2020-2028) ($MN)
  • Table 11 Global Genotyping Market Outlook, By Technology (2020-2028) ($MN)
  • Table 12 Global Genotyping Market Outlook, By Sequencing (2020-2028) ($MN)
  • Table 13 Global Genotyping Market Outlook, By Pyrosequencing (2020-2028) ($MN)
  • Table 14 Global Genotyping Market Outlook, By NGS (2020-2028) ($MN)
  • Table 15 Global Genotyping Market Outlook, By Sanger Sequencing (2020-2028) ($MN)
  • Table 16 Global Genotyping Market Outlook, By Microarrays (2020-2028) ($MN)
  • Table 17 Global Genotyping Market Outlook, By PCR (2020-2028) ($MN)
  • Table 18 Global Genotyping Market Outlook, By Real-Time PCR (2020-2028) ($MN)
  • Table 19 Global Genotyping Market Outlook, By Digital PCR (2020-2028) ($MN)
  • Table 20 Global Genotyping Market Outlook, By MALDI-TOF (2020-2028) ($MN)
  • Table 21 Global Genotyping Market Outlook, By Capillary Electrophoresis (2020-2028) ($MN)
  • Table 22 Global Genotyping Market Outlook, By Restricted Fragment Length Polymorphism (2020-2028) ($MN)
  • Table 23 Global Genotyping Market Outlook, By Single-stranded Conformation Polymorphism (2020-2028) ($MN)
  • Table 24 Global Genotyping Market Outlook, By Amplified Fragment Length Polymorphism (2020-2028) ($MN)
  • Table 25 Global Genotyping Market Outlook, By Other Technologies (2020-2028) ($MN)
  • Table 26 Global Genotyping Market Outlook, By Application (2020-2028) ($MN)
  • Table 27 Global Genotyping Market Outlook, By Diagnostic & Personalized Medicine (2020-2028) ($MN)
  • Table 28 Global Genotyping Market Outlook, By Animal Genetics (2020-2028) ($MN)
  • Table 29 Global Genotyping Market Outlook, By Pharmacogenomics (2020-2028) ($MN)
  • Table 30 Global Genotyping Market Outlook, By Other Applications (2020-2028) ($MN)
  • Table 31 Global Genotyping Market Outlook, By End User (2020-2028) ($MN)
  • Table 32 Global Genotyping Market Outlook, By Pharmaceutical & Biopharmaceutical Companies (2020-2028) ($MN)
  • Table 33 Global Genotyping Market Outlook, By Academic Institutes (2020-2028) ($MN)
  • Table 34 Global Genotyping Market Outlook, By Research & Diagnostic Laboratories (2020-2028) ($MN)
  • Table 35 Global Genotyping Market Outlook, By Other End Users (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.